Home » Newsletters » BioWorld Science

BioWorld Science

March 22, 2012

View Archived Issues

Merck & Co. uncovers gene polymorphisms linked to MK-7246 pharmacokinetics

Fate Therapeutics discloses new hedgehog pathway activators

Canadian university patents new SHIP-1 modulators

Novartis discloses updated phase II data on secukinumab

Cardium Therapeutics begins phase III registration study

Korean trials assess two Lapscovery-based drugs

Galapagos receives milestone payment from Janssen Pharmaceutica

Addex Pharmaceuticals changes name

Ablynx extends global strategic Nanobody alliance

Abbott discloses new name for future research-based company

Medistem updates on endometrial regenerative cell therapy development

Treatment begins in global phase II/III hemophilia B trial

Flagyl approved for additional indication in Japan

NCI study reveals novel candidate biomarkers of hepatocellular carcinoma

Health Canada approves grass pollen immunotherapy

Green Cross clear to conduct GreenGene F study in U.S.

Merck & Co. presents new potential cancer therapies

Novel chemokine CCR4 receptor antagonists developed at GSK

New tyrosine-protein kinase inhibitors reported

Chroma Therapeutics designs new histone deacetylase inhibitors

Allergan scientists discover novel prostanoid receptor antagonists

Cerus gives update on INTERCEPT Blood System

Line extension for Taxol approved in Japan

Enrollment complete in phase II MN-221 trial

Noven completes phase III program for low-dose paroxetine mesilate

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...